Gilead and Kite Showcase Oncology Pipeline Momentum at ASCO and EHA 2026
Event summary
- Gilead and Kite will present over 25 abstracts at ASCO (May 29–June 2) and EHA (June 11–14) 2026, including six oral presentations.
- Key data highlights include new analyses for Trodelvy in first-line metastatic triple-negative breast cancer (mTNBC) and anito-cel for relapsed/refractory multiple myeloma (RRMM).
- ASCO will feature PFS2 data for Trodelvy plus Keytruda in mTNBC, a measure of long-term clinical effect.
- Kite will present Phase 1 results for KITE-753, an enhanced DuoCore CAR T-cell therapy for relapsed/refractory B-cell lymphoma.
The big picture
Gilead and Kite are reinforcing their leadership in oncology with a diversified portfolio spanning ADCs and cell therapies. The data presented at ASCO and EHA 2026 underscore their strategic focus on durable clinical impact across solid tumors and hematologic malignancies. The company's ability to sustain this momentum will depend on regulatory success and operational execution in a competitive landscape.
What we're watching
- Regulatory Approvals
- Whether Trodelvy's combination with Keytruda gains regulatory approval for first-line mTNBC, given its investigational status.
- Pipeline Execution
- The pace at which Gilead and Kite advance late-stage programs like anito-cel and KITE-753 toward commercialization.
- Competitive Positioning
- How Gilead and Kite's ADC and CAR T-cell therapy data will influence their standing in the rapidly evolving oncology market.
Related topics